VTRS · 8-K · 20260806PR000037
Regulatory Remediation Costs
Viatris Inc · 2026-08-06 · Importance 40 · Surprise 42 · In source text
In May 2026, the U.S. FDA inspected Viatris's oral solid dose manufacturing facility in Nashik, India, and issued Form 483 observations. Viatris initiated a comprehensive remediation plan supported by independent third-party subject matter experts, and ongoing remediation has caused intermittent disruptions after production resumed. The company expects the February fire, temporary suspension, and intermittent disruptions to reduce second-half 2026 total revenue by $100 million to $150 million.
Key facts
- In May, FDA inspected the Nashik oral solid dose facility and issued Form 483 observations; remediation plan initiated and activities ongoing with intermittent disruptions source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | committed | — | In May, FDA inspected the Nashik oral solid dose facility and issued Form 483 observations; remediation plan initiated and activities… |